CAR T-cell therapy for B-cell cancers like chronic lymphocytic leukemia (CLL) utilizes genetically engineered T-cells that target a specific protein on the surface of cancerous B-cells to kill them. This type of therapy has greatly helped improve many relapsed/refractory CLL patients’ remission rates and length of remission through its administration in clinical trials for CLL. Relapsed means the disease came back after a prior line of therapy and refractory means the patient’s body rejected prior medicines, allowing the cancer cells to advance despite treatment.
Current FDA-approved CAR T-cell therapies for more aggressive B-cell cancers like diffuse large B-cell lymphoma (DLBCL) include axi-cel (Yescarta), brexu-cel (Tecartus), tisa-cel (Kymriah), and liso-cel (Breyanzi). These types of CAR T-cells are autologous meaning the patient sends in a sample of their own cells to the pharmaceutical company who then re-engineers the patient’s T-cells to add the CAR gene. CAR T-cell therapy for CLL is currently in clinical trials, and there are no FDA-approved CAR T-cell therapies for CLL at this time. Click here to learn more about CLL clinical trials and why you should consider joining one.
In this article, we’ll be discussing points that CLL patients can take into consideration when reviewing if receiving a CAR T-cell therapy in a clinical trial setting would be right for them.
Long-term data from 10 studies, spanning 24-123 months, on CD19-targeted CAR T-cell therapies indicate that patients with relapsed and/or refractory B-cell lymphoma or CLL experience overall response rates (ORR) (full and/or partial reduction of cancer signs/symptoms) of 44-91% and complete response (CR) rates (full reduction of cancer signs/symptoms) of 28-68%. Every study highlighted a group of patients maintaining responses for at least 2 years post-infusion without additional treatments. One study with longer follow-up showed that of the 43 patients treated with a precursor to axi-cel (Yescarta), 58% achieved a CR, with 76% of them sustaining long-term remission ranging from 43 to 113 months. Another study using tisa-cel (Kymriah) reflected a 55% CR rate, with 60% of these patients still in remission after 5 years. These outcomes suggest that some relapsed/refractory B-cell lymphoma patients might be cured using CD19-targeted CAR T-cell therapy without needing further treatments.
The possible short-term side effects of CAR T-cell therapy along with their side effect solutions include:
The long-term side-effect of CAR T-cell therapy and its solution:
For the best CAR T-cell therapy outcomes, several factors play a crucial role in long-term remission:
Richter’s transformation (RT) is a rare occurrence when CLL turns into a more aggressive B-cell lymphoma like DLBCL which is difficult to treat. Current first-line chemotherapy treatments like R-CHOP have a 30% success rate, and there's no standard care for relapsed patients. Recent studies have shown promise with CAR T-cell therapies for RT patients. One of these studies reported a 71% complete response rate using a CD19 CAR T-cell therapy with a CD28 costimulatory domain (a molecule that helps fully activate the CAR T-cell).
Similarly, Dr. Adam Kittai's study found positive results with axi-cel (Yescarta) for RT patients. Out of the 9 studied, 8 of the patients saw a decrease in RT symptoms after CAR T-cell treatment with 6 patients still being in remission at the median follow-up time of 6 months.
Researchers wanted to review if it would be more effective to treat CLL patients with CAR T-cell therapy in combination with a BTK inhibitor as opposed to treating patients with CAR T-cell therapy by itself. Data from the TRANSCEND CLL 004 study showed:
New CAR T-cell therapies are being researched. Areas of study include the below:
Several points CLL patients can take into consideration when reviewing if receiving CAR T-cell therapy is right for them include insights into long-term outcomes, how side effects both short-term and long-term are managed, the factors that influence remission, how the therapy is applied for CLL patients that have undergone Richter’s transformation, the effectiveness of CAR T-cell therapy in combination with a BTK inhibitor, and future areas of study for this type of therapy. Interested in receiving CAR T-cell therapy for your CLL? Apply through the clinical trial finder here. Search "CAR T" in the keyword bar and enter your location to find a CAR T-cell therapy clinical trial near you. You can also ask your CLL specialist about ongoing CAR T-cell therapy clinical trials near you.
CAR T-cell therapy for B-cell cancers like chronic lymphocytic leukemia (CLL) utilizes genetically engineered T-cells that target a specific protein on the surface of cancerous B-cells to kill them. This type of therapy has greatly helped improve many relapsed/refractory CLL patients’ remission rates and length of remission through its administration in clinical trials for CLL. Relapsed means the disease came back after a prior line of therapy and refractory means the patient’s body rejected prior medicines, allowing the cancer cells to advance despite treatment.
Current FDA-approved CAR T-cell therapies for more aggressive B-cell cancers like diffuse large B-cell lymphoma (DLBCL) include axi-cel (Yescarta), brexu-cel (Tecartus), tisa-cel (Kymriah), and liso-cel (Breyanzi). These types of CAR T-cells are autologous meaning the patient sends in a sample of their own cells to the pharmaceutical company who then re-engineers the patient’s T-cells to add the CAR gene. CAR T-cell therapy for CLL is currently in clinical trials, and there are no FDA-approved CAR T-cell therapies for CLL at this time. Click here to learn more about CLL clinical trials and why you should consider joining one.
In this article, we’ll be discussing points that CLL patients can take into consideration when reviewing if receiving a CAR T-cell therapy in a clinical trial setting would be right for them.
Long-term data from 10 studies, spanning 24-123 months, on CD19-targeted CAR T-cell therapies indicate that patients with relapsed and/or refractory B-cell lymphoma or CLL experience overall response rates (ORR) (full and/or partial reduction of cancer signs/symptoms) of 44-91% and complete response (CR) rates (full reduction of cancer signs/symptoms) of 28-68%. Every study highlighted a group of patients maintaining responses for at least 2 years post-infusion without additional treatments. One study with longer follow-up showed that of the 43 patients treated with a precursor to axi-cel (Yescarta), 58% achieved a CR, with 76% of them sustaining long-term remission ranging from 43 to 113 months. Another study using tisa-cel (Kymriah) reflected a 55% CR rate, with 60% of these patients still in remission after 5 years. These outcomes suggest that some relapsed/refractory B-cell lymphoma patients might be cured using CD19-targeted CAR T-cell therapy without needing further treatments.
The possible short-term side effects of CAR T-cell therapy along with their side effect solutions include:
The long-term side-effect of CAR T-cell therapy and its solution:
For the best CAR T-cell therapy outcomes, several factors play a crucial role in long-term remission:
Richter’s transformation (RT) is a rare occurrence when CLL turns into a more aggressive B-cell lymphoma like DLBCL which is difficult to treat. Current first-line chemotherapy treatments like R-CHOP have a 30% success rate, and there's no standard care for relapsed patients. Recent studies have shown promise with CAR T-cell therapies for RT patients. One of these studies reported a 71% complete response rate using a CD19 CAR T-cell therapy with a CD28 costimulatory domain (a molecule that helps fully activate the CAR T-cell).
Similarly, Dr. Adam Kittai's study found positive results with axi-cel (Yescarta) for RT patients. Out of the 9 studied, 8 of the patients saw a decrease in RT symptoms after CAR T-cell treatment with 6 patients still being in remission at the median follow-up time of 6 months.
Researchers wanted to review if it would be more effective to treat CLL patients with CAR T-cell therapy in combination with a BTK inhibitor as opposed to treating patients with CAR T-cell therapy by itself. Data from the TRANSCEND CLL 004 study showed:
New CAR T-cell therapies are being researched. Areas of study include the below:
Several points CLL patients can take into consideration when reviewing if receiving CAR T-cell therapy is right for them include insights into long-term outcomes, how side effects both short-term and long-term are managed, the factors that influence remission, how the therapy is applied for CLL patients that have undergone Richter’s transformation, the effectiveness of CAR T-cell therapy in combination with a BTK inhibitor, and future areas of study for this type of therapy. Interested in receiving CAR T-cell therapy for your CLL? Apply through the clinical trial finder here. Search "CAR T" in the keyword bar and enter your location to find a CAR T-cell therapy clinical trial near you. You can also ask your CLL specialist about ongoing CAR T-cell therapy clinical trials near you.
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family.